| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | 81U49K9009 |
Structure
| InChI Key | NTRKMGDUWYBLMS-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
Physicochemical Descriptors
| Property Name | Value |
|---|---|
| Molecular Formula | C20H30ClN7O7S |
| Molecular Weight | 548.02 |
| AlogP | 0.09 |
| Hydrogen Bond Acceptor | 8.0 |
| Hydrogen Bond Donor | 6.0 |
| Number of Rotational Bond | 10.0 |
| Polar Surface Area | 194.99 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 2.0 |
| Heavy Atoms | 31.0 |
Pharmacology
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Ion channel
Ligand-gated ion channel
Epithelial sodium channel
|
- | 8 | - | - | - |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Cystic Fibrosis | 1 | D003550 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL4297254 |
| FDA SRS | 81U49K9009 |
| PubChem | 11548455 |
| SureChEMBL | SCHEMBL15092803 |
| ChEMBL | CHEMBL212432 |
| FDA SRS | 2WWN8F640E |
| Guide to Pharmacology | 4280 |
| PubChem | 11548455 |
| SureChEMBL | SCHEMBL2015162 |
CONTENTS